Quadrant Biosciences has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Clarifi COVID-19 test kit.
Developed in partnership with State University of New York (SUNY) Upstate Medical University, the saliva swab test determines the presence or absence of SARS-CoV-2 viral RNA, according to the company. It contains a saliva collection swab and the reagents needed to perform the analysis. Clarifi is available now for clinical laboratories serving patients through physicians' offices, urgent care clinics, and hospitals, Quadrant said.
